Shares of Syros Pharmaceuticals Inc (NASDAQ:SYRS) have received a consensus rating of “Buy” from the ten ratings firms that are covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation, five have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $13.86.
Several research firms have weighed in on SYRS. Oppenheimer began coverage on Syros Pharmaceuticals in a report on Monday, June 1st. They issued a “buy” rating and a $11.00 price target on the stock. Piper Sandler raised their price target on Syros Pharmaceuticals from $14.00 to $18.00 in a report on Friday, August 7th. ValuEngine raised Syros Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, August 11th. BidaskClub raised Syros Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, August 7th. Finally, Zacks Investment Research raised Syros Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $10.00 price objective on the stock in a report on Saturday, May 9th.
Shares of NASDAQ:SYRS traded down $0.28 on Friday, hitting $13.62. The company’s stock had a trading volume of 22,303 shares, compared to its average volume of 323,589. The company has a 50-day simple moving average of $11.53 and a 200 day simple moving average of $8.80. Syros Pharmaceuticals has a 1 year low of $4.26 and a 1 year high of $14.64. The company has a market capitalization of $631.52 million, a PE ratio of -8.09 and a beta of 1.53. The company has a debt-to-equity ratio of 0.73, a current ratio of 4.85 and a quick ratio of 4.85.
Syros Pharmaceuticals (NASDAQ:SYRS) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.02. Syros Pharmaceuticals had a negative return on equity of 94.59% and a negative net margin of 1,114.79%. On average, equities research analysts expect that Syros Pharmaceuticals will post -1.52 earnings per share for the current fiscal year.
In related news, insider Eric R. Olson sold 4,963 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $13.00, for a total transaction of $64,519.00. Following the transaction, the insider now directly owns 4,963 shares in the company, valued at approximately $64,519. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Richard A. Young sold 5,990 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $8.75, for a total value of $52,412.50. Following the transaction, the director now owns 359,161 shares in the company, valued at $3,142,658.75. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 130,611 shares of company stock worth $1,462,898. 14.80% of the stock is owned by corporate insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of SYRS. Ameritas Investment Partners Inc. grew its position in Syros Pharmaceuticals by 40.9% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,667 shares of the company’s stock worth $39,000 after acquiring an additional 1,065 shares during the last quarter. Bank of Montreal Can bought a new stake in shares of Syros Pharmaceuticals in the 2nd quarter worth approximately $40,000. BNP Paribas Arbitrage SA grew its position in shares of Syros Pharmaceuticals by 166.3% in the 1st quarter. BNP Paribas Arbitrage SA now owns 10,685 shares of the company’s stock worth $63,000 after buying an additional 6,672 shares during the last quarter. Citigroup Inc. grew its position in shares of Syros Pharmaceuticals by 23.4% in the 1st quarter. Citigroup Inc. now owns 12,627 shares of the company’s stock worth $75,000 after buying an additional 2,391 shares during the last quarter. Finally, SG Americas Securities LLC bought a new stake in shares of Syros Pharmaceuticals in the 1st quarter worth approximately $82,000. Institutional investors and hedge funds own 98.22% of the company’s stock.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients.
Featured Story: FinTech
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.